Cytokine Release Syndrome Market

Key Highlights:

 

  • In 2021, the total market size of cytokine release syndrome was USD 4.3 million which is expected to rise during the study period (2019–2032).
  • In the year 2021, the total incident cases of cytokine release syndrome were 48,853 in the 7MM which are expected to grow during the study period, i.e., 2019–2032.
  • According to the DelveInsight, in the year 2021, the total incident cases of cytokine release syndrome were 11,559 in the United States which are expected to grow during the study period, i.e., 2019–2032.

 

Request a sample to unlock the CAGR for Cytokine release syndrome Market.

 

DelveInsight's "Cytokine Release Syndrome (CRS)- Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the cytokine release syndrome, historical and forecasted epidemiology as well as the cytokine release syndrome market trends in the United States, the EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The cytokine release syndrome market report provides current treatment practices, emerging drugs, cytokine release syndrome market share of the individual therapies, and current and forecasted cytokine release syndrome market size from 2019 to 2032 segmented by seven major markets. The report also covers current cytokine release syndrome treatment practice/algorithm, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • The EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2019–2032

 

Cytokine Release Syndrome (CRS) Understanding and Treatment Algorithm

The DelveInsight’s cytokine release syndrome epidemiology report gives a thorough understanding of cytokine release syndrome. Cytokine release syndrome is a systemic inflammatory response triggered by various factors such as infections and certain drugs causing pathologic over-activation of T cells, leading to hypersecretion of cytokines by T cells and other immune cell types. CRS can also occur after certain types of immunotherapy, such as CAR T-cell therapy, and is sometimes called cytokine storm or cytokine-associated toxicity.

 

Symptoms of Cytokine Release Syndrome are caused by a widespread immune response affecting different organ systems in the body. The symptoms range from mild, flu-like symptoms to severe life-threatening manifestations of the overshooting inflammatory response. Mild symptoms include fever, fatigue, headache, rash, arthralgia, and myalgia. Severe symptoms include hypotension as well as high fever and can progress to an uncontrolled systemic inflammatory response with vasopressor-requiring circulatory shock, vascular leakage, disseminated intravascular coagulation, and multi-organ system failure.

 

The pathophysiology of Cytokine Release Syndrome is incompletely understood. CRS usually occurs due to on-target effects induced by binding of the bispecific antibody or CAR T-cell receptor to its antigen and subsequent activation of bystander immune cells and non-immune cells, such as endothelial cells. Activation of the bystander cells results in the massive release of a range of cytokines. The initial activation of CAR T cells results in the distortion of the cytokine network driving the inflammatory process in Cytokine Release Syndrome is unknown (Shimabukuro-Vornhagen et al., 2018).

 

Currently, no established Cytokine Release Syndrome diagnostic criteria are available. An accurate approach included three key findings: compatible clinical symptoms, elevated biomarkers, and recent treatment with any biological agent. Clinically, CRS patients present with unspecific syndromes making the diagnosis challenging. It is important to distinguish CRS from other inflammatory disorders that present with similar clinical signs and symptoms but require different treatment.

 

Cytokine Release Syndrome Treatment

There is very little evidence-based data regarding the management of CRS. Currently, no guidelines are available for the standard treatment and it is solely based on the experience of a small group of individuals.

 

Tocilizumab, a humanized monoclonal immunoglobulin G1k antibody that binds to soluble and membrane-bound IL-6 receptors thereby inhibiting IL-6 signaling, is the only FDA-approved drug for the treatment of severe or life-threatening CRS (Varadarajan et al., 2020).

 

Depending on the clinical center both tocilizumab (IL-6R targeting monoclonal antibody) and siltuximab (chimeric anti-IL-6 monoclonal antibody) have been used to control CRS. Considering approval of tocilizumab for CRS management by both the US FDA and EMA, there have been concerns about the possible elevation of IL-6 due to blockade of the receptor that subsequently leads to accumulation of this effector cytokine in the CNS. Therefore, the prospect of siltuximab being included to intervene in CRS is probable based on the rationale that it can lead to a favorable outcome in cases of passive diffusion of IL-6 into the CNS. Currently, the greater effectiveness of siltuximab over tocilizumab is highly debatable, and these concerns highlight the need for direct comparative studies that elucidate the efficacy of tocilizumab and siltuximab.

Cytokine Release Syndrome (CRS) Epidemiology

The cytokine release syndrome epidemiology division provides insights about the historical and current cytokine release syndrome patient pool and forecasted trends for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

 

Cytokine Release Syndrome Key Findings

The Cytokine Release Syndrome epidemiology covered in the report provides a historical as well as cytokine release syndrome epidemiology scenario in the 7MM covering the United States, the EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

 

Cytokine Release Syndrome Prevalence

 

In the year 2021, the total incident cases of cytokine release syndrome were 48,853 in the 7MM which are expected to grow during the study period, i.e., 2019–2032.

 

The Cytokine Release Syndrome epidemiology covered in the report provides historical as well as forecasted cytokine release syndrome epidemiology (segmented as Total Incident Cases of Cytokine Release Syndrome, Grade-specific cases of Cytokine Release Syndrome (CRS), Cytokine Release Syndrome Cases by CAR-T Therapies, Cytokine Release Syndrome Cases by Bispecific Antibodies, and Cytokine Release Syndrome Cases by Allogenic Transplant in the 7MM covering the United States, the EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.

Country Wise- Cytokine Release Syndrome (CRS) Epidemiology

  • The epidemiology segment also provides the cytokine release syndrome epidemiology data and findings across the United States, the EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • According to the DelveInsight, in the year 2021, the total incident cases of cytokine release syndrome were 11,559 in the United States which are expected to grow during the study period, i.e., 2019–2032.
  • The highest number of total incident cases of cytokine release syndrome was observed in Germany among the EU5 countries with 8,222 cases in 2021 which are expected to grow during the study period, i.e., 2019–2032.
  • In the year 2021, the total incident cases of cytokine release syndrome were 3,792 in Japan which are expected to grow during the study period, i.e., 2019–2032.

Cytokine Release Syndrome (CRS) Drug Chapters

The drug chapter segment of the cytokine release syndrome report encloses the detailed analysis of cytokine release syndrome marketed drugs and late-stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the cytokine release syndrome clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

 

Emerging Cytokine Release Syndrome Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for cytokine release syndrome treatment.

 

Cytokine Release Syndrome Market Outlook

 

Cytokine Release Syndrome (CRS) Market Outlook

IL-6 has emerged as a critical cytokine in exacerbating the progression of CRS in T-cell-engaging therapies. Depending on the clinical center, both tocilizumab (IL-6 receptor targeting monoclonal antibody) and siltuximab (chimeric anti-IL-6 monoclonal antibody) have been used to control CRS. In light of the approval of Actemra (tocilizumab) for management of CRS by both the US FDA and European Medicines Agency, there have been concerns raised about the possible elevation of IL-6 due to blockade of the receptor that subsequently leads to accumulation of this effector cytokine in the CNS. Therefore, the prospect of siltuximab being included to intervene in CRS is probable based on the rationale that it can lead to a favorable outcome in cases of passive diffusion of IL-6 into the CNS. Currently, the greater effectiveness of siltuximab over tocilizumab is highly debatable, and these concerns highlight the need for direct comparative studies that elucidate the efficacy of tocilizumab and siltuximab. Nevertheless, strategies to target IL-6 have been particularly effective in alleviating CAR T-cell-mediated CRS and will continue to be used as a component of the first-line treatment.

 

The use of corticosteroids following CAR T-cell therapy is reserved for clinical cases where toxicities are refractory to IL-6 targeting therapies. Currently, a standard intervention for CRS consists of dexamethasone 10 mg/kg intravenous (IV) every 6 h or methylprednisolone 1 mg/kg IV every 12 h in moderate to high-grade CRS. Despite existing reservations about broad immunosuppression as well as impairment of T-cell function, corticosteroids remain valuable when paired with the first-line of treatments to manage moderate-to-severe CRS. Systemic corticosteroids are effective in dampening CRS due to their established anti-inflammatory properties. Due to early concern about steroids inhibiting CAR-T activity and expansion, its use early in CRS onset was relatively restricted to preserve CAR-T antitumor activity. Typically, corticosteroids are reserved for cases of CRS refractory to tocilizumab or being administered concomitantly with tocilizumab for high-grade CRS or CRS that occurs with associated neurotoxicity.

 

With the growing use of T-cell-engaging therapies, there is an urgent need for clinical trials that improve the evidence base to treat CRS. The current management strategies for CRS are predominantly based on biological reasoning, expert opinion, and retrospective analyses. To further improve the safety and effectiveness of the clinical management of CRS, randomized controlled trials that evaluate different treatment strategies for CRS are necessary.

 

In short, efficacious pharmacologic options for managing the most incident and disabling phases of CRS are extremely limited. Treatments that work in both phases of the disorder are especially rare; therefore, new treatments are desperately needed.

 

According to DelveInsight, the cytokine release syndrome (CRS) market in 7MM is expected to witness a major change in the study period 2019–2032.

 

Cytokine Release Syndrome Key Findings

The cytokine release syndrome market size in the 7MM is expected to change during the study period 2019–2032. The therapeutic market of cytokine release syndrome in the seven major markets is expected to increase during the study period (2019–2032).

In 2021, the total Cytokine Release Syndrome market size was USD 4.3 million which is expected to rise during the study period (2019–2032).

 

The United States: Cytokine Release Syndrome Market Outlook

The total Cytokine Release Syndrome market size in the United States accounted for USD 3.5 million in 2021 which is expected to rise during the study period (2019–2032).

 

The EU5 Countries: Cytokine Release Syndrome Market Outlook

In the EU5, the total Cytokine Release Syndrome market size was USD 0.8 million in 2021, which is expected to rise during the study period (2019–2032).

 

Cytokine Release Syndrome

 

Japan: Cytokine Release Syndrome Market Outlook

In Japan, the total Cytokine Release Syndrome market size was USD 0.01 million in 2021, which is expected to rise during the study period (2019–2032).

Cytokine Release Syndrome (CRS) Uptake

This section focuses on the rate of uptake of the potential Cytokine Release Syndrome drugs recently launched in the cytokine release syndrome market or expected to get launched in the market during the study period 2019-2032. The analysis covers cytokine release syndrome market uptake by drugs; patient uptake by therapies; and sales of each drug.

 

This helps in understanding the drugs with the most rapid uptake, and reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Cytokine Release Syndrome (CRS) Development Activities

The Cytokine Release Syndrome report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses cytokine release syndrome key players involved in developing targeted therapeutics.

 

Pipeline Development Activities

The report covers detailed information on collaborations, acquisition, and merger, licensing patent details, and other information for cytokine release syndrome emerging therapies.

Reimbursement Scenario in Cytokine Release Syndrome (CRS)

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SMEs ' opinions working in the cytokine release syndrome domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or cytokine release syndrome market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitively and Market Intelligence analysis of the cytokine release syndrome Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Report Metrics

Details

Study Period

2019 to 2032

Base Year

2021

Forecast Period

2022 to 2032

CAGR

Request Sample to Know

Market Size

USD 4.3 million in 2021

Key Companies

Incyte Corporation, Swedish Orphan Biovitrum (sobi), Genentech

Scope of the Cytokine Release Syndrome Report

  • The report covers the descriptive overview of cytokine release syndrome, explaining its causes, signs and symptoms, pathophysiology, diagnosis, and currently available therapies
  • Comprehensive insight has been provided into the cytokine release syndrome epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for cytokine release syndrome are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of the cytokine release syndrome market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global cytokine release syndrome market.

Cytokine Release Syndrome Market Report Highlights

  • In the coming years, the cytokine release syndrome market is set to change due to the upcoming therapies with novel route of administrations which are under investigation and ongoing research in the cytokine release syndrome; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence cytokine release syndrome R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for cytokine release syndrome. The launch of emerging therapies will significantly impact the cytokine release syndrome market.
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for cytokine release syndrome.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Cytokine Release Syndrome (CRS) Report Insights

  • Cytokine Release Syndrome Patient Population
  • Cytokine Release Syndrome Therapeutic Approaches
  • Cytokine release syndrome (CRS) Pipeline Analysis
  • Cytokine release syndrome (CRS) Market Size and Trends
  • Cytokine Release Syndrome Market Opportunities
  • Impact of upcoming Cytokine Release Syndrome Therapies

Cytokine Release Syndrome (CRS) Report Key Strengths

  • 11 Years Forecast
  • 7MM Coverage
  • Cytokine release syndrome (CRS) Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Cytokine Release Syndrome Market
  • Cytokine Release Syndrome Drugs Uptake

Cytokine Release Syndrome (CRS) Report Assessment

  • Current Cytokine Release Syndrome Treatment Practices
  • Cytokine Release Syndrome Unmet Needs
  • Cytokine Release Syndrome Pipeline Product Profiles
  • Cytokine Release Syndrome Market Attractiveness

Key Questions

Cytokine Release Syndrome Market Insights:

  • What was the cytokine release syndrome drug class share (%) distribution in 2019 and how it would look like in 2032?
  • What would be the cytokine release syndrome total market size as well as market size by therapies across the 7MM during the forecast period (2019-2032)?
  • What are the key findings of the market across 7MM and which country will have the largest cytokine release syndrome market size during the forecast period (2019-2032)?
  • At what CAGR, the cytokine release syndrome market is expected to grow by 7MM during the forecast period (2019-2032)?
  • What would be the cytokine release syndrome market outlook across the 7MM during the forecast period (2019-2032)?
  • What would be the cytokine release syndrome market growth till 2032, and what will be the resultant market Size in the year 2032?
  • How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?

 

Cytokine Release Syndrome Epidemiology Insights:

  • What are the disease risk, burden, and regional/ethnic differences of cytokine release syndrome?
  • What are the key factors driving the epidemiology trend for seven major markets covering the United States, the EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What is the historical cytokine release syndrome patient pool in seven major markets covering the United States, the EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of cytokine release syndrome in seven major markets covering the United States, the EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • Where will be the growth opportunities in the 7MM concerning the patient population about cytokine release syndrome?
  • Out of all 7MM countries, which country would have the highest prevalent population of cytokine release syndrome during the forecast period (2019-2032)?
  • At what CAGR the patient population is expected to grow by 7MM during the forecast period (2019-2032)?

 

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the cytokine release syndrome treatment in addition to the approved therapies?
  • What are the current treatment guidelines for the treatment of cytokine release syndrome in the USA, Europe, and Japan?
  • What are the cytokine release syndrome marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
  • How many companies are developing therapies for the treatment of cytokine release syndrome?
  • How many therapies are in-development by each company for cytokine release syndrome treatment?
  • How many are emerging therapies in mid-stage, and late stage of development for cytokine release syndrome treatment?
  • What are the key collaborations (Industry - Industry, Industry-Academia), mergers and acquisitions, licensing activities related to the cytokine release syndrome therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies being developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for cytokine release syndrome and their status?
  • What are the current challenges faced in drug development?
  • What are the key designations that have been granted for the emerging therapies for cytokine release syndrome?
  • What are the global historical and forecasted markets of cytokine release syndrome?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the cytokine release syndrome market
  • To understand the future market competition in the cytokine release syndrome market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for cytokine release syndrome in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for the cytokine release syndrome market
  • To understand the future market competition in the cytokine release syndrome market

Frequently Asked Questions

What is Cytokine Release Syndrome?
Cytokine release syndrome (CRS) is an acute systemic inflammatory condition marked by fever and various organ failures that is linked to CAR-T cell therapy, therapeutic antibodies, and haploidentical allogeneic transplantation.
What is the Cytokine Release Syndrome Market Size in 7MM?
The total Cytokine Release Syndrome market size was accounted for USD 4.3 Million in the year 2021 and is estimated to grow during the study period (2019-2032).
Who are the leading companies in the Cytokine Release Syndrome Market Landscape?
The key players in the Cytokine Release Syndrome market who are in different phases of developing Obesity Therapies are - Incyte Corporation, Swedish Orphan Biovitrum (sobi), Genentech, and others.
What are the Key strengths of the Cytokine Release Syndrome Market Report?
Key strengths of the Cytokine Release Syndrome Market Report are 11 Years Forecast, 7MM Coverage, Epidemiology Segmentation, Market Size, Drug Uptake, Pipeline Therapies, Market Drivers and Market Barriers, and upcoming Cytokine Release Syndrome market trends.
Which country is expected to account for the most significant prevalent cases for Cytokine Release Syndrome in the 7MM?
The United States is expected to account for the highest prevalent Cytokine Release Syndrome cases.

1. Key Insights

2. Report Introduction

3. Cytokine Release Syndrome (CRS) Market Overview at a Glance

3.1. Drug-class Share (%) Distribution of CRS in 2019

3.2. Drug-class Share (%) Distribution of CRS in 2032

4. Executive Summary of Cytokine Release Syndrome (CRS)

5. Epidemiology and Market Methodology

6. Future Prospects

7. Disease Background and Overview

7.1. Introduction

7.2. Symptoms

7.3. Causes and Risk Factors

7.4. Pathophysiology

7.5. CRS in patients with COVID-19 infection

7.6. Diagnosis of CRS

7.6.1. Grading of CRS

7.7. Biomarkers for CRS

7.8. Treatment of CRS

7.9. Treatment algorithms

7.10. Treatment Guidelines

7.10.1. ASCO Guidelines for the management of CRS

7.10.2. Recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE), and the European Hematology Association (EHA) for the management of CRS in patients receiving CAR T-cell therapy

8. Cytokine Release Syndrome Patient Journey

9. Epidemiology and Patient Population

9.1. Key Findings

9.2. Assumptions and Rationale

9.3. Epidemiology Scenario in the 7MM

9.3.1. Total Incident Cases of CRS in the 7MM

9.3.2. Grade specific Cases of CRS in the 7MM

9.3.3. CRS Cases by CAR-T Therapies in the 7MM

9.3.4. CRS Cases by Bispecific Antibodies in the 7 MM

9.3.5. CRS Cases by Allogeneic Transplant in the 7 MM

9.4. Epidemiology Scenario in the United States

9.4.1. Total Incidence Cases of CRS in the United States

9.4.2. Grade-specific Cases of CRS in the United States

9.4.3. CRS Cases by CAR-T Therapies in the United States

9.4.4. CRS Cases by Bispecific Antibodies in the United States

9.4.5. CRS Cases by Allogeneic Transplant in the United States

9.5. Epidemiology Scenario in the EU5

9.5.1. Total Incidence Cases of CRS in the EU5

9.5.2. Grade specific Cases of CRS in the EU5

9.5.3. CRS Cases by CAR-T Therapies in the EU5

9.5.4. CRS Cases by Bispecific antibodies in the EU5

9.5.5. CRS Cases by Allogenic Transplant in the EU5

9.6. Epidemiology Scenario in Japan

9.6.1. Total Incident Cases of CRS in Japan

9.6.2. Grade-specific CRS Cases in Japan

9.6.3. CRS Cases by CAR-T therapies in Japan

9.6.4. CRS Cases by Bispecific Antibodies in Japan

9.6.5. CRS Cases by Allogenic Transplant in Japan

10. Key Endpoint in CRS Clinical Trials

11. Marketed Cytokine Release Syndrome Therapies

11.1. ACTEMRA/ROACTEMRA (tocilizumab): Genentech

11.1.1. Drug description

11.1.2. Regulatory milestones

11.1.3. Other developmental activities

11.1.4. Pivotal clinical trial

12. Emerging Cytokine Release Syndrome Drugs

12.1. Itacitinib: (Incyte Corporation)

12.1.1. Product description

12.1.2. Other developmental activities

12.1.3. Clinical developmental

12.2. KINERET (anakinra): Swedish Orphan Biovitrum (sobi)

12.2.1. Product description

12.2.2. Other development activities

12.2.3. Clinical development

13. Cytokine Release Syndrome (CRS) 7 Major Market Analysis

13.1. Key Findings

13.2. Market Outlook

13.3. Key Market Forecast Assumptions

13.4. 7MM Market Size of Cytokine Release Syndrome (CRS)

13.4.1. Total Market Size of CRS in the 7MM

13.4.2. Market Size by Therapies of CRS in the 7MM

13.5. Market Size of Cytokine Release Syndrome (CRS) in the United States

13.5.1. Total Market Size of CRS in the United States

13.5.2. Market Size by Therapies of CRS in the United States

13.6. Market Size of Cytokine Release Syndrome (CRS) in the EU5

13.6.1. Total Market Size of CRS in the EU5

13.6.2. Market Size by Therapies of CRS in the EU5

13.7. Market Size of Cytokine Release Syndrome (CRS) in Japan

13.7.1. Total Market Size of CRS in Japan

13.7.2. Market Size by Therapies of CRS in Japan

14. Market Access and Reimbursement

15. KOL Views

16. SWOT Analysis

17. Cytokine Release Syndrome Unmet needs

18. Appendix

18.1. Bibliography

18.2. Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

List of Table

Table 1: Summary of Cholangiocarcinoma, Market, Epidemiology, and Key Events (2019–2032)

Table 2 Clinical Risk Factors for Severe CRS

Table 3 Diagnostic Criteria for Severe CRS

Table 4 Differential Diagnoses of CRS-related HLH/MAS

Table 5 Published CRS grading systems

Table 6 ASTCT CRS Consensus Grading

Table 7 Recommended Anti-cytokine Agents and Dosing (where reasonable data are available)

Table 8: Total Incidence Cases of CRS (2019–2032)

Table 9: Grade-specific Cases of CRS in the 7MM (2019–2032)

Table 10: CRS Cases by CAR-T Therapies in the 7MM (2019–2032)

Table 11: CRS Cases by Bispecific Antibodies in the 7MM (2019–2032)

Table 12: CRS cases by Allogeneic Transplant in the 7MM (2019–2032)

Table 13: Total Incidence Cases of CRS in the United States (2019–2032)

Table 14: Grade specific Cases of CRS in the United States (2019–2032)

Table 15: CRS Cases by CAR-T Therapies in the United States (2019–2032)

Table 16: CRS Cases by Bispecific AB in the United States (2019–2032)

Table 17: CRS cases by Allogeneic Transplant  in the United States (2019–2032)

Table 18: Total Incidence Cases of CRS in the  EU5 (2019–2032)

Table 19: Grade specific Cases of CRS in the EU5 (2019–2032)

Table 20: CRS Cases  by CAR-T Therapies in the EU5 (2019–2032)

Table 21: CRS Cases by Bispecific antibodies in the EU5 (2019–2032)

Table 22: CRS Cases by Allogenic Transplant in the EU5 (2019–2032)

Table 23: Total Incident Cases of CRS in Japan (2019–2032)

Table 24: Grade-specific CRS Cases in Japan (2019-2032)

Table 25: CRS Cases by CAR-T therapies in Japan (2019-2032)

Table 26: CRS Cases by Bispecific Antibodies in Japan

Table 27: CRS Cases by Allogenic Transplant in Japan (2019–2032)

Table 28: ASTCT CRS Consensus Grading

Table 29: Lee Criteria for CRS Grading System

Table 30: Penn Criteria for CRS Grading System

Table 31: Itacitinib, Clinical Trial Description, 2022

Table 32: Itacitinib, Clinical Trial Description, 2022

Table 33: KINERET (anakinra), Clinical Trial Description, 2022

Table 34: Key Market Forecast Assumptions for Itacitinib

Table 35: Key Market Forecast Assumptions for KINERET (anakinra)

Table 36: 7MM Market Size of CRS in USD Million (2019–2032)

Table 37: Market Size by Therapies of CRS in the 7MM in USD Million (2019–2032)

Table 38: Market Size of CRS in the United States, in USD Million (2019–2032)

Table 39: Market Size by Therapies of CRS in the United States, in USD Million (2019–2032)

Table 40: Market Size of CRS in the EU5, in USD Million (2019–2032)

Table 41: Market Size by Therapies in the EU5, in USD Million (2019–2032)

Table 42: Market Size of CRS in Japan, USD Million (2019–2032)

Table 43: Market Size by Therapies of CRS in Japan, USD Million (2019–2032)

List of Figures

Figure 1: Cytokines and Their Functions

Figure 2: Clinical Presentation of CRS

Figure 3: Causes of CRS

Figure 4: Mechanism of CAR T-cell Therapy and CRS

Figure 5: Pathophysiology of CRS

Figure 6: Pathways Leading to CRS

Figure 7: Pathophysiology and Grading of CRS

Figure 8: Grading and Management of CRS

Figure 9: CRS Management Algorithm

Figure 10: CRS Management Recommendations

Figure 11: ASCO Guidelines for the Management of CRS

Figure 12: Grading and Management of CRS

Figure 13: Total Incidence Cases of CRS in the 7MM (2019–2032)

Figure 14: Grade-specific Cases of CRS in the 7MM (2019–2032)

Figure 15: CRS Cases by CAR-T Therapies in the 7MM (2019–2032)

Figure 16: CRS Cases by Bispecific AB in the 7MM (2019–2032)

Figure 17: CRS cases by Allogeneic Transplant in the 7MM (2019–2032)

Figure 18: Total Incidence Cases of CRS in the United States (2019–2032)

Figure 19: Grade-specific Cases of CRS in the United States (2019–2032)

Figure 20: CRS Cases by CAR-T Therapies in the United States (2019–2032)

Figure 21: CRS Cases by Bispecific Antibodies in the United States (2019–2032)

Figure 22: CRS cases by Allogeneic Transplant in the United States (2019–2032)

Figure 23: Total Incidence Cases of CRS in  EU5 (2019–2032)

Figure 24: Grade specific Cases of CRS in EU5 (2019–2032)

Figure 25: CRS Cases by CAR-T Therapies in EU5 (2019–2032)

Figure 26: CRS Cases by Bispecific antibodies in EU5 (2019–2032)

Figure 27: CRS Cases by Allogenic Transplant in the EU5 (2019–2032)

Figure 28: Total Incident Cases of CRS in Japan (2019–2032)

Figure 29: Grade-specific CRS Cases in Japan

Figure 30: CRS Cases by CAR-T therapies in Japan (2019-2032)

Figure 31: CRS cases by Bispecific Antibodies in Japan

Figure 32: CRS Cases by Allogenic Transplant in Japan (2019–2032)

Figure 33: Market Size of CRS in the 7MM, USD Million (2019–2032)

Figure 34: Market Size by Therapies of CRS in the 7MM, USD Million (2019–2032)

Figure 35: Market Size of CRS in the United States, USD Million (2019–2032)

Figure 36: Market Size by Therapies of CRS in the United States, USD Million (2019–2032)

Figure 37: Market Size of CRS in the EU5, USD Million (2019–2032)

Figure 38: Market Size by Therapies of CRS in the EU5, USD Million (2019–2032)

Figure 39: Market Size of CRS in Japan, USD Million (2019–2032)

Figure 40: Market Size by Therapies of CRS in Japan, USD Million (2019–2032)

Figure 41: Unmet Needs

Incyte Corporation
Swedish Orphan Biovitrum (sobi)
Genentech

 

Forward to Friend

Need A Quote